SCHEMBL30337057

SCHEMBL30337057

O=C(O)c1c(Cl)ccc(Nc2ncc3ccccc3n2)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 1/20 0.44
AURKA O14965 4/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
JAK2 O60674 1/20 0.38
AURKB Q96GD4 1/20 0.38
PBRM1 Q86U86 1/20 0.37
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR4 P22455 1/20 0.37
FGFR3 P22607 1/20 0.37
LRRK2 Q5S007 1/20 0.37
ATM Q13315 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
FDPS P14324 1/20 0.37
WEE1 P30291 1/20 0.37
ULK1 O75385 1/20 0.37
ROCK1 Q13464 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23978627 1.00 MAP3K5 (0.44) MAP3K5AURKAHDAC3HDAC1HDAC2
SCHEMBL23978706 0.87 MAP3K5 (0.45) MAP3K5FGFR1FGFR2FGFR4FGFR3
SCHEMBL23979058 0.79 ITGB1 (0.39) MAP3K5
SCHEMBL23978646 0.75 INSR (0.36) MAP3K5FGFR1FGFR2FGFR4FGFR3
SCHEMBL23978630 0.73 FGFR1 (0.34) MAP3K5FGFR1FGFR2FGFR4FGFR3
SCHEMBL6467426 0.71 MAP3K5 (0.54) MAP3K5AURKAJAK2AURKBFGFR1
SCHEMBL30336865 0.71 FGFR4 (0.36) AURKAHDAC3HDAC1HDAC2HDAC6
SCHEMBL23978659 0.71 FGFR4 (0.36) AURKAHDAC3HDAC1HDAC2HDAC6
SCHEMBL167891 0.68 MAP3K5 (0.60) MAP3K5AURKAJAK2AURKBFGFR1
SCHEMBL31381352 0.68 MAP3K5 (0.60) MAP3K5AURKAJAK2AURKBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115916176-A Inhibitors of alpha 2 beta 1 integrin and methods of use thereof 加利福尼亚大学董事会 2023-04-04 CN disclosed